Skip to content
PICO Portalanswers from OpenAlex

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

PaperCitations, authors & open-access status

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib is a paper indexed in PICO Portal from OpenAlex.

How many citations does High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib have?

PICO Portalcitation count

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib has 82 citations in the OpenAlex counts PICO Portal stores.

When was High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib published?

PICO Portalyear

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib has 2021 year in the PICO Portal index.

What is the open-access status of High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib?

PICO Portaloa status

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib has bronze oa status in the PICO Portal index.

What is the DOI of High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib?

PICO Portaldoi

The DOI for High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib is on the source record.

What is the PMID of High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib?

PICO Portalpmid

The PMID for High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib is on the source record.

What is the OpenAlex record for High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib?

PICO Portalopenalex

The OpenAlex for High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial